NanoLogix, Inc.
NNLX
Other OTC0.00
USD
- -
- -
ISIN
US6300761078
CUSIP
630076107
Return %
Stock
S&P500
1Y
0.00
26.53
3Y
- -
76.60
5Y
-99.59
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Bret T. Barnhizer
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 843 North Main Street Hubbard OH United States of America 44425
- IPO Date
- Sep 8, 2009
- Website
- nanologix.com
- Similar Companies
- Business
- NanoLogix, Inc. (NNLX) is a biotechnology company that develops, manufactures, and commercializes rapid diagnostic test kits and filled petri plates for the detection of viable bacteria, microorganisms, and viruses. The company offers core products including FlatPack Petri Plates packaged in vacuum-sealed, argon-flushed formats for extended shelf life exceeding two years at room temperature; BioNanoPore kits utilizing water-permeable membranes for interaction with organic, inorganic molecules, and proteins; N-Assay Diagnostics, an antibody-based assay for simultaneous pathogen identification and antibiotic susceptibility testing; and Rapid Viral Assay technology configurable for viruses such as COVID-19, HIV, HPV, Hepatitis, MERS, and SARS with sub-one-hour detection capabilities. These products serve applications in medical diagnostics, pharmaceutical testing, industrial monitoring, veterinary medicine, environmental analysis, national defense, and homeland security. NanoLogix operates primarily from its headquarters and production facilities in Hubbard, Ohio, where it maintains cleanrooms for manufacturing and an R&D laboratory; founded in 1989, the company targets global markets through its patented technologies in microbiology and bioremediation. Recent developments include the patent-pending status achieved in 2020 for its sub-one-hour COVID-19 detection technology under the USPTO's prioritized examination program, alongside ongoing commercialization efforts for point-of-care and home-use viral assays; earlier advancements encompass N-Assay presentations at major conferences like AACC 2017 and configurations for Ebola and Enterovirus detection, with no major acquisitions, funding rounds, or reorganizations reported in the last two years.